Top Page
Firebrick Pharma Limited
(Sydney:FRE)
Firebrick Pharma Limited (FRE) vs. iShares MSCI Australia ETF (EWA)
Firebrick Pharma Limited Business Overview & Revenue Model
Firebrick Pharma Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 515.51K | 293.42K | 14.52K | 830.00 | 4.12K | 422.00K |
| Gross Profit | 326.90K | 104.82K | -22.78K | 830.00 | 4.12K | 421.48K |
| EBITDA | -2.53M | -2.86M | -1.17M | -6.81M | -4.86M | -2.86M |
| Net Income | -2.63M | -2.63M | -1.18M | -6.80M | -3.80M | -2.44M |
Balance Sheet | ||||||
| Total Assets | 1.83M | 1.83M | 2.41M | 2.98M | 8.73M | 11.77M |
| Cash, Cash Equivalents and Short-Term Investments | 983.35K | 983.35K | 824.78K | 2.35M | 7.14M | 11.16M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 271.28K | 271.28K | 291.07K | 506.44K | 450.10K | 214.80K |
| Stockholders Equity | 1.56M | 1.56M | 2.12M | 2.48M | 8.28M | 11.55M |
Cash Flow | ||||||
| Free Cash Flow | -1.86M | -1.86M | -2.35M | -5.78M | -4.23M | -1.95M |
| Operating Cash Flow | -1.78M | -1.78M | -2.34M | -5.78M | -4.20M | -1.94M |
| Investing Cash Flow | -82.98K | -82.98K | -134.00 | -1.62K | -32.54K | -16.07K |
| Financing Cash Flow | 2.02M | 2.02M | 815.21K | 996.65K | 10.23M | 3.01M |
Firebrick Pharma Limited Technical Analysis
Firebrick Pharma Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$265.72M | -2.88 | -90.93% | ― | 456.50% | -457.14% | |
44 Neutral | AU$196.64M | -7.44 | ― | ― | ― | 0.66% | |
44 Neutral | AU$108.11M | -12.79 | -47.98% | ― | 700.00% | 26.88% | |
42 Neutral | AU$15.09M | -5.44 | -143.50% | ― | 1920.53% | -89.39% | |
40 Underperform | AU$2.17M | -4.33 | -28.49% | ― | ― | 46.43% | |
38 Underperform | AU$54.20M | -6.42 | -37.78% | ― | 2.33% | 12.50% |
Firebrick Pharma Limited Corporate Events
Firebrick Pharma Limited held its Annual General Meeting where all resolutions, including the special resolution for the approval of the 7.1A Mandate, were passed. This successful meeting indicates strong shareholder support and positions the company for continued growth and expansion in its market, potentially benefiting stakeholders through enhanced market presence and product offerings.
Firebrick Pharma Limited recently held its Annual General Meeting, where Executive Chairman Dr. Peter Molloy presented information about the company’s current status and future prospects. The presentation emphasized that the information provided is for informational purposes only and is not intended as investment advice. It highlighted the company’s caution regarding forward-looking statements, noting that actual results may differ due to various risks and uncertainties.
Firebrick Pharma Limited has announced a change in its auditing firm, transitioning from BDO Audit Pty Ltd to Criterion Audit Pty Ltd effective December 1, 2025. This change aims to align audit services with the company’s size and nature, resulting in cost reductions. The appointment of the new auditor will be ratified at the next Annual General Meeting in November 2026.
Firebrick Pharma Limited has announced the commencement of manufacturing for its new product, Nasodine Throat Spray, which will be exported starting November 2025. This new product, a 1.0% povidone-iodine formulation, offers a convenient alternative to traditional throat gargles and will first be launched in Singapore. The company has received export approval from the TGA and plans to market the product through its licensing partner, Innorini Life Sciences, targeting healthcare professionals and retail channels by mid-2026. This expansion marks the first new addition to the Nasodine range since the Nasodine Nasal Spray, signaling future growth in the brand’s product line.
Firebrick Pharma Limited has announced its Annual General Meeting (AGM) will be held virtually on November 26, 2025, allowing shareholders to participate online. The meeting will cover the company’s financial statements, the adoption of the remuneration report, the re-election of director Rick Legleiter, and the approval of a mandate to issue additional equity securities. Shareholders are encouraged to vote by proxy to ensure their participation.
Firebrick Pharma Limited has secured an additional investment of $102,000 from its strategic partner Pharma Nutria N.A., Inc. (PNAI) in the Philippines. This investment, made at a 31% premium over the previous closing price, aims to restore PNAI’s holding to above 5% following a recent placement to other investors. The move underscores PNAI’s confidence in Firebrick’s leadership and the potential of its product Nasodine, with the partnership expected to enhance Firebrick’s market presence in the Philippines.
Firebrick Pharma Limited has announced the issuance of 7,680,000 unquoted options, expiring on October 1, 2029, at an exercise price of $0.12. These securities are part of an employee incentive scheme, which is not intended to be listed on the ASX, reflecting the company’s strategy to motivate and retain key personnel, potentially impacting its operational efficiency and market positioning.